Literature DB >> 563994

Multiple sclerosis among Orientals and Caucasians in Hawaii: a reappraisal.

H Shibasaki, M M Okihiro, Y Kuroiwa.   

Abstract

A comparative retrospective study of Oriental and Caucasian patients with multiple sclerosis (MS) failed to reveal significant differences between the two groups regarding historical data, such as sex ratio, mode of onset, age at onset, duration of illness, and clinical course, suggesting that MS is essentially the same disease in both groups. However, certain clinical features were more frequent in Orientals: Severe bilateral optic nerve involvement; acute transverse myelopathy, especially of a recurrent nature; clear-cut sensory levels; and optic-spinal-brainstem and optic-spinal involvement. Environmental factors may also be responsible.

Entities:  

Mesh:

Year:  1978        PMID: 563994     DOI: 10.1212/wnl.28.2.113

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Cortical deafness in multiple sclerosis.

Authors:  T Tabira; S Tsuji; T Nagashima; T Nakajima; Y Kuroiwa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-05       Impact factor: 10.154

2.  Pattern reversal visual evoked potentials in Japanese patients with multiple sclerosis.

Authors:  H Shibasaki; Y Kuroiwa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

3.  Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis.

Authors:  I Nakashima; K Fujihara; N Okita; S Takase; Y Itoyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

4.  A clinical comparative study of multiple sclerosis and neuro-Behçet's syndrome.

Authors:  S Motomura; T Tabira; Y Kuroiwa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-03       Impact factor: 10.154

Review 5.  Epidemiologic evidence for multiple sclerosis as an infection.

Authors:  J F Kurtzke
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.